Luggen M[au] - Search Results

Year	Number of Results
1972	1
1985	2
1987	2
1988	1
1989	3
1990	1
1991	2
1993	1
1994	1
1995	1
1996	3
1998	2
1999	2
2001	1
2002	2
2004	2
2005	1
2006	2
2007	4
2008	1
2009	1
2011	2
2012	2
2015	1
2016	2
2018	1
2019	1
2021	1
2022	2
2024	1
2025	2

1

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.

Feist E, Fleischmann RM, Fatenejad S, Bukhanova D, Grishin S, Kuzkina S, Luggen M, Nasonov E, Samsonov M, Smolen JS. Feist E, et al. Among authors: luggen m. Ann Rheum Dis. 2024 Oct 21;83(11):1454-1464. doi: 10.1136/ard-2023-225473. Ann Rheum Dis. 2024. PMID: 38955475 Free PMC article. Clinical Trial.

2

Remodeling the pyramid--a concept whose time has not yet come.

Hess EV, Luggen ME. Hess EV, et al. Among authors: luggen me. J Rheumatol. 1989 Sep;16(9):1175-6. J Rheumatol. 1989. PMID: 2572698 No abstract available.

3

Trials are short, disease long: measuring drug utility beyond clinical trials.

Luggen ML. Luggen ML. J Rheumatol. 2004 Feb;31(2):205-6. J Rheumatol. 2004. PMID: 14760785 Review. No abstract available.

4

T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation.

Vincenti F, Luggen M. Vincenti F, et al. Among authors: luggen m. Annu Rev Med. 2007;58:347-58. doi: 10.1146/annurev.med.58.080205.154004. Annu Rev Med. 2007. PMID: 17020493 Review.

5

Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction.

Gulati G, Iffland PH 2nd, Janigro D, Zhang B, Luggen ME. Gulati G, et al. Among authors: luggen me. Clin Rheumatol. 2016 Dec;35(12):2989-2997. doi: 10.1007/s10067-016-3339-1. Epub 2016 Jun 29. Clin Rheumatol. 2016. PMID: 27357716

6

Treatment of rheumatic diseases in the elderly.

Luggen M. Luggen M. Geriatr Nurs. 2001 May-Jun;22(3):118-9. doi: 10.1067/mgn.2001.117228. Geriatr Nurs. 2001. PMID: 11410761 No abstract available.

7

Depression-, Pain-, and Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus.

Chalhoub NE, Luggen ME. Chalhoub NE, et al. Among authors: luggen me. Int J Rheumatol. 2022 May 5;2022:6290736. doi: 10.1155/2022/6290736. eCollection 2022. Int J Rheumatol. 2022. PMID: 35572065 Free PMC article.

8

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.

Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, Samsonov M, Smolen JS, Fleischmann RM. Feist E, et al. Among authors: luggen me. Ann Rheum Dis. 2022 Dec;81(12):1661-1668. doi: 10.1136/ard-2022-222630. Epub 2022 Sep 15. Ann Rheum Dis. 2022. PMID: 36109142 Free PMC article. Clinical Trial.

9

Monitoring methotrexate toxicity in juvenile idiopathic arthritis.

Kocharla L, Taylor J, Weiler T, Ting TV, Luggen M, Brunner HI. Kocharla L, et al. Among authors: luggen m. J Rheumatol. 2009 Dec;36(12):2813-8. doi: 10.3899/jrheum.090482. Epub 2009 Nov 16. J Rheumatol. 2009. PMID: 19918032

10

Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE.

Luggen ME, Gulati G, Zhang B, Willis RA, Gonzalez EB. Luggen ME, et al. Clin Rheumatol. 2016 Jan;35(1):93-9. doi: 10.1007/s10067-015-3114-8. Epub 2015 Nov 12. Clin Rheumatol. 2016. PMID: 26563139

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Results by year